JUL 23, 2020 6:11 AM PDT

Prostate Cancer: To Treat or Not to Treat

WRITTEN BY: Tara Fernandez

After a prostate cancer diagnosis, urologists do not always initiate immediate clinical intervention. In those with low-risk prostate cancer, a “wait and see” approach is usually recommended — a strategy known as active surveillance. During this post-diagnostic monitoring period, the patient’s health care team keeps a close eye on their condition via regular testing. However, exactly which patients should go down the active surveillance track remains a grey zone.

Mieke Van Hemelrijck from King’s College London is a lead researcher and part of the GAP3 consortium, the world’s biggest active surveillance prostate cancer database. Van Hemelrijck and colleagues have recently developed a tool to gauge risk levels in prostate cancer patients, allowing them to make data-driven medical decisions.

"Current methods of deciding whether or not to recommend treatment are not reliable,” said Van Hemelrijck. 

“Our analysis shows that we should be able to produce a single global methodology, which will give accurate estimates of how aggressive these cancers are. These will feed directly into the treatment decision, and give men the reassurance they need to decide on treatment". The work was presented at the virtual European Association of Urology Congress.

Prostate cancers are detected with a prostate-specific antigen, or PSA, blood test, and most of the time, these tumors are considered low risk. In low-risk patients, the tumor is small, contained within the prostate, and is growing so slowly that it is extremely unlikely that it will become life-threatening. In these cases, treatment strategies are unnecessary, especially considering the side effects: impotence, leaking urine, and painful bowel movements. In some countries, up to 80 percent of men diagnosed with prostate cancer opt for active surveillance over treatment.

In a big leap forward, researchers of the GAP3 Consortium have developed the prostate cancer tool called a nomogram — a treatment calculator tool that provides advice on whether or not to pursue treatment. The researchers have created the world’s biggest database on active surveillance with data from over 14,000 patients. It includes information on age, size, tumor status, PSA levels, genetic factors, and the time spent on active surveillance.

"Not surprisingly, we have found that even accounting for these factors there was still differences in outcomes between participating centers. But this work has shown that it will be possible to produce a nomogram which can guide treatment,” said Van Hemelrijck. 

“Just as importantly, the work shows which additional factors need to be included in the nomogram in future to enable us to eliminate this variation and produce accurate estimates of tumor aggressiveness".

 

 

Source: European Association of Urology, EurekAlert.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 05, 2021
Genetics & Genomics
Genetics May Help Us Learn Who is at Risk From a Folate Deficiency
JUL 05, 2021
Genetics May Help Us Learn Who is at Risk From a Folate Deficiency
Folate is necessary for a healthy pregnancy; low folate levels can lead to neural tube defects. A lack of folate, a nutr ...
JUL 29, 2021
Clinical & Molecular DX
Sewage Sleuths: Tracking COVID Variants in Wastewater
JUL 29, 2021
Sewage Sleuths: Tracking COVID Variants in Wastewater
Since the dawn of the pandemic, one of the biggest challenges has been monitoring the crowned enemy as it spread through ...
AUG 05, 2021
Clinical & Molecular DX
Wearable Patch Senses Blood Vessel Blockages
AUG 05, 2021
Wearable Patch Senses Blood Vessel Blockages
The cardiovascular system is like a network of highways, filled with an estimated 25 trillion red blood cells that conti ...
AUG 24, 2021
Clinical & Molecular DX
A New Chapter in Metastatic Breast Cancer Biomarkers
AUG 24, 2021
A New Chapter in Metastatic Breast Cancer Biomarkers
For patients diagnosed with metastatic breast cancer, it’s often not the primary tumor that has fatal consequences ...
SEP 01, 2021
Clinical & Molecular DX
Will Childhood Cancer Survivors Go On to Have Broken Hearts?
SEP 01, 2021
Will Childhood Cancer Survivors Go On to Have Broken Hearts?
Patients are seven times more likely to have a heart attack or stroke than the general population after receiving treatm ...
SEP 16, 2021
Clinical & Molecular DX
Your T-Shirt Could Soon Tell You if Your Heart Is Ok
SEP 16, 2021
Your T-Shirt Could Soon Tell You if Your Heart Is Ok
Forget uncomfortable chest straps or clunky wristbands—thanks to a new innovation in nanotechnology, your t-shirt ...
Loading Comments...